THE PROTECTIVE EFFECT OF L-ARGININE ON MYOCARDIAL INJURY AND ENDOTHELIAL FUNCTION FOLLOWING ISCHEMIA AND REPERFUSION IN THE PIG

被引:54
作者
PERNOW, J
URIUDA, Y
WANG, QD
LI, XS
NORDLANDER, R
RYDEEN, L
机构
[1] Department of Cardiology, Karolinska Hospital
关键词
L-ARGININE; ENDOTHELIUM; ISCHEMIA REPERFUSION; MYOCARDIAL INFARCT; NITRIC OXIDE; VASODILATATION;
D O I
10.1093/oxfordjournals.eurheartj.a060456
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The protective effect of the nitric oxide (NO) substrate L-arginine on myocardial ischaemia/reperfusion injury was studied in pigs. Four groups were subjected to 45 min ischaemia and 4h reperfusion. One control group received coronary venous retroinfusion of saline, the second retroinfusion of L-arginine (1 mg.kg-1.min-1), the third retroinfusion of L-arginine plus the NO synthase inhibitor N(omega)-nitro-L-arginine (L-NNA), and the fourth systemic i.v. infusion of L-arginine (1mg.kg-1.min-1). The infarct size in the L-arginine retroinfusion group was 35 +/- 5% of the myocardial area at risk compared to 76 +/- 5% in saline treated controls (P<0.001). In pigs receiving the combination of retroinfused L-arginine and L-NNA the infarct size was similar to that of controls (79 +/- 4%). Systemic i.v. infusion of L-arginine did not influence the infarct size. Administration of L-NNA + L-arginine slightly increased arterial blood pressure during ischaemia but the groups did not differ in blood pressure, heart rate, rate-pressure product, left ventricular dP/dt or coronary blood flow during the reperfusion period. Coronary vasodilatation by acetylcholine was significantly compromised in the saline retroinfusion group, but not in the L-arginine retroinfusion group as compared to pigs not subjected to myocardial ischaemia. The results show that coronary venous retroinfusion of L-arginine reduces myocardial infarct size and preserves endothelial function via a local action which seems to be related to maintained nitric oxide formation.
引用
收藏
页码:1712 / 1719
页数:8
相关论文
共 35 条
[1]   APPARENT HYDROXYL RADICAL PRODUCTION BY PEROXYNITRITE - IMPLICATIONS FOR ENDOTHELIAL INJURY FROM NITRIC-OXIDE AND SUPEROXIDE [J].
BECKMAN, JS ;
BECKMAN, TW ;
CHEN, J ;
MARSHALL, PA ;
FREEMAN, BA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (04) :1620-1624
[2]   NITRIC-OXIDE IS AN IMPORTANT DETERMINANT OF CORONARY FLOW IN THE ISOLATED BLOOD PERFUSED RAT-HEART [J].
BOUMA, P ;
FERDINANDY, P ;
SIPKEMA, P ;
ALLAART, CP ;
WESTERHOF, N .
BASIC RESEARCH IN CARDIOLOGY, 1992, 87 (06) :570-584
[3]  
BRESNAHAN GF, 1974, AM J CARDIOL, V33, P82, DOI 10.1016/0002-9149(74)90742-5
[4]   EARLY PHASE ACUTE MYOCARDIAL INFARCT SIZE QUANTIFICATION - VALIDATION OF THE TRIPHENYL TETRAZOLIUM CHLORIDE TISSUE ENZYME STAINING TECHNIQUE [J].
FISHBEIN, MC ;
MEERBAUM, S ;
RIT, J ;
LANDO, U ;
KANMATSUSE, K ;
MERCIER, JC ;
CORDAY, E ;
GANZ, W .
AMERICAN HEART JOURNAL, 1981, 101 (05) :593-600
[5]   ENDOTHELIUM-DERIVED RELAXING FACTOR INHIBITS INVITRO PLATELET-AGGREGATION [J].
FURLONG, B ;
HENDERSON, AH ;
LEWIS, MJ ;
SMITH, JA .
BRITISH JOURNAL OF PHARMACOLOGY, 1987, 90 (04) :687-692
[6]   SUPEROXIDE ANION IS INVOLVED IN THE BREAKDOWN OF ENDOTHELIUM-DERIVED VASCULAR RELAXING FACTOR [J].
GRYGLEWSKI, RJ ;
PALMER, RMJ ;
MONCADA, S .
NATURE, 1986, 320 (6061) :454-456
[7]   BENEFICIAL-EFFECTS OF CORONARY VENOUS RETROINFUSION BUT NOT LEFT ATRIAL ADMINISTRATION OF SUPEROXIDE-DISMUTASE ON MYOCARDIAL NECROSIS IN PIGS [J].
HATORI, N ;
TADOKORO, H ;
SATOMURA, K ;
MIYAZAKI, A ;
FISHBEIN, MC ;
RYDEN, L ;
CORDAY, E ;
DRURY, JK .
EUROPEAN HEART JOURNAL, 1991, 12 (03) :442-450
[8]   REPERFUSION INDUCED INJURY - MANIFESTATIONS, MECHANISMS, AND CLINICAL RELEVANCE (REPRINTED FROM TRENDS IN CARDIOVASCULAR MEDICINE, VOL 1, PG 233-40, 1991) [J].
HEARSE, DJ ;
BOLLI, R .
CARDIOVASCULAR RESEARCH, 1992, 26 (02) :101-108
[9]   REPERFUSION OF ISCHEMIC MYOCARDIUM [J].
HEARSE, DJ .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1977, 9 (08) :605-616
[10]   ISCHEMIA, REPERFUSION, AND THE DETERMINANTS OF TISSUE-INJURY [J].
HEARSE, DJ .
CARDIOVASCULAR DRUGS AND THERAPY, 1990, 4 :767-776